FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 119 filers reported holding FATE THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $24,000 | +41.2% | 1,500 | 0.0% | 0.01% | +66.7% |
| Q2 2018 | $17,000 | +13.3% | 1,500 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $15,000 | -44.4% | 1,500 | -66.7% | 0.00% | 0.0% |
| Q4 2017 | $27,000 | -20.6% | 4,500 | -47.1% | 0.00% | -25.0% |
| Q3 2017 | $34,000 | +61.9% | 8,500 | +30.8% | 0.00% | +100.0% |
| Q2 2017 | $21,000 | -30.0% | 6,500 | 0.0% | 0.00% | -66.7% |
| Q1 2017 | $30,000 | – | 6,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,073,190 | $26,599,000 | 26.59% |
| Polaris Venture Management Co. V, L.L.C. | 1,823,186 | $23,391,000 | 24.97% |
| Casdin Capital, LLC | 2,550,000 | $32,717,000 | 5.60% |
| Redmile Group, LLC | 10,359,666 | $132,915,000 | 5.34% |
| Aquilo Capital Management, LLC | 697,096 | $8,944,000 | 4.33% |
| Eversept Partners, LP | 165,000 | $2,116,950 | 1.15% |
| Artal Group S.A. | 2,150,000 | $27,585,000 | 1.02% |
| AlpInvest Partners B.V. | 26,925 | $345,000 | 0.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,654,865 | $21,232,000 | 0.85% |
| Lisanti Capital Growth, LLC | 142,760 | $1,832,000 | 0.74% |